We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
59.00 | 3.18% | 1,913.00 | 1,916.00 | 1,918.00 | 1,920.00 | 1,861.00 | 1,861.00 | 522,491 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 22.08 | 4.24B |
TIDMHIK
RNS Number : 6033O
Hikma Pharmaceuticals Plc
18 May 2018
Hikma Pharmaceuticals PLC
Voting Results of 2018 Annual General Meeting
LONDON, 18 May 2018 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 18 May 2018 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 17 were passed as ordinary resolutions and Resolutions 18 to 21 were passed as special resolutions.
As previously announced, Dr. Ronald Goode retired from the Board at the close of the AGM.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 28 March 2018) is set out below. The number of Ordinary Shares in issue on 18 May 2018 was 240,940,604.
Resolution Votes % Votes % Total Withheld For Against Cast ------------------------- ------------ ------- ----------- ------ ------------ ---------- 1. To receive the 2017 report and accounts 196,394,230 99.96 72,200 0.04 196,466,430 245,708 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 2. To approve a final dividend of 23 cents per share 196,485,553 99.89 225,796 0.11 196,711,349 788 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 3. To re-appoint PricewaterhouseCoopers LLP as auditors 196,099,742 99.69 610,679 0.31 196,710,421 1,717 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 4.To authorise the Audit Committee to determine the auditors' remuneration 196,703,625 100.00 5,721 0.00 196,709,346 2,792 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 5. To elect Siggi Olafsson as a director 195,815,999 99.55 894,642 0.45 196,710,641 1,497 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 6. To re-elect Said Darwazah as a director 190,417,700 96.80 6,298,814 3.20 196,716,514 1,622 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 7. To re-elect Mazen Darwazah as a director 193,925,828 98.58 2,783,900 1.42 196,709,728 2,410 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 8. To re-elect Robert Pickering as a director 190,879,517 98.02 3,848,509 1.98 194,728,026 1,984,111 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 9.To re-elect Ali Al-Husry as a director 195,245,623 99.26 1,464,293 0.74 196,709,916 2,222 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 10. To re-elect Patrick Butler as a director 193,317,043 98.28 3,393,072 1.72 196,710,115 2,022 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 11. To re-elect Dr. Jochen Gann as a director 195,107,616 99.19 1,602,499 0.81 196,710,115 2,022 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 12. To re-elect John Castellani as a director 193,529,031 98.38 3,180,885 1.62 196,709,916 2,222 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 13. To re-elect Dr. Pamela Kirby as a director 190,289,183 96.74 6,421,682 3.26 196,710,865 1,272 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 14. To re-elect Nina Henderson as a director 192,848,157 98.04 3,862,508 1.96 196,710,665 1,472 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 15. To approve the remuneration report for the year ended 31 December 2017 169,750,519 86.36 26,815,358 13.64 196,565,877 146,261 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 16. To approve and adopt the 2018 Management Incentive Plan 195,620,834 99.45 1,088,481 0.55 196,709,315 2,822 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 17. Authority to allot shares 166,598,638 84.69 30,112,333 15.31 196,710,971 1,167 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 18. To dis-apply pre-emption rights for general purposes 196,660,802 99.97 50,469 0.03 196,711,271 867 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 19. To dis-apply pre-emption rights for an acquisition or other capital investment 195,530,359 99.40 1,179,711 0.60 196,710,070 2,067 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 20. To authorise the Company to purchase its own shares 195,989,881 99.68 621,703 0.32 196,611,584 100,553 ------------------------- ------------ ------- ----------- ------ ------------ ---------- 21. To authorise the Company to hold general meetings on no less than 14 clear days' notice 187,831,722 95.49 8,878,028 4.51 196,709,750 2,388 ------------------------- ------------ ------- ----------- ------ ------------ ----------
Declaration of final dividend
The dividend of 23 cents per share will be paid on 24 May 2018 to shareholders on the register on 6 April 2018. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.3521 to GBP1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC Peter Speirs Company Secretary +44 20 7399 2670 Susan Ringdal VP for Investor Relations and Strategy +44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.
LEI: 549300BNS685UXH4JI75
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUWRURWRAVAAR
(END) Dow Jones Newswires
May 18, 2018 08:01 ET (12:01 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions